Roche to Acquire Poseida Therapeutics for ~$1.5B
Shots:
- Roche will acquire Poseida for $9/share in cash, strengthening its CAR-T therapy portfolio, with the deal closing in Q1’25
- Roche will also pay a total of $4/share non-tradeable CVR as milestones ($2 for pivotal trial of P-BCMA-ALLO1 by Dec 2028, $1 for a pivotal trial of P-CD19CD20-ALLO1 or P-BCMACD19-ALLO1 in autoimmune indication by Dec 2034 & $1 for P-BCMA-ALLO1’s sale by Dec 2031), valuing the deal at ~$1.5B
- Acquisition adds Poseida’s P-BCMA-ALLO1 (in P-I for MM), P-CD19CD20-ALLO1 (in P-I for B-cell malignancies, with FDA INDs for multiple sclerosis & SLE), another allogeneic dual CAR-T therapy for hematologic malignancy, P-MUC1C-ALLO1 (in P-I for solid tumors), GMP manufacturing capabilities plus genomic pre-clinical medicines & related tech
Ref: Roche | Image: Poseida
Related News:- Flare Therapeutics Inks Pact with Roche to Develop Small Molecules Targeting Undrugged Transcription Factors in Oncology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
